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ABSTRACT 
    Peak flow-targeted adaptive servo ventilation (ASVpf) suppresses both obstructive (OSA) and central 
sleep apnoea (CSA). Although high hours of positive airway pressure (PAP) use improves quality of 
life, long-term compliance is problematic. We evaluated ASVpf use in patients with heart failure and 
reduced ejection fraction with either OSA or CSA to determine the short and long-term predictors of 
ASV pf compliance.  
     Of 177 patients randomised to ASVpf, compliance data were available at one and 12 months post-
randomisation in 91 with OSA and 45 with CSA. Among patients with OSA, ASVpf use was 4.6 [2.9] h 
per day at one month but decreased to 4.1 [4.7] h at 12 months (p=0.04). Among patients with CSA, 
median ASVpf use was 5.2 [4.0] h per day at one month and 5.2 [3.5] h per day at 12 months (p=0.52). 
The only predictor of ASVpf use at 12 months was hours of use at one month (OR 2.02: CI 1.58-2.60, 
p<0.01).  
     These data indicate better compliance with ASVpf than previously reported for other PAP devices in 
patients with cardiovascular diseases. Hours of daily use at one month predicted compliance at 12 
months, indicating that if good short-term compliance is achieved, this effect can be sustained long-
term.  
To the Editor: 
Despite its effectiveness in suppressing sleep-disordered breathing (SDB), positive airway 
pressure therapy (PAP) is not always well tolerated by patients, and long-term adherence can be 
problematic. Recently, two multi-centre,  randomized clinical trials (RCT) tested the effects of PAP 
for patients with cardiovascular disease and co-existing SDB on morbidity and mortality with 
negative outcomes [1, 2]. Relatively poor adherence to PAP therapy (mean 3.7 h/day and 3.3 h/day 
respectively) in these two trials, might have contributed to their poor results. Indeed, higher PAP use 
per day is associated with better clinical outcomes  than lower use [3].  
The “Effect of Adaptive Servo-ventilation on Survival and Cardiovascular Hospital Admissions 
in Patients with Heart Failure and Sleep Apnoea” (ADVENT-HF) trial is a multinational RCT assessing 
the effects of treating SDB with peak flow targeted adaptive servo-ventilation (ASVpf) on morbidity 
and mortality in patients with heart failure (HF) and reduced ejection fraction (HFrEF) [4].  The purpose 
of this study was to determine the short and long-term predictors of ASVpf adherence in an inception 
cohort of the ADVENT-HF trial. The trial has been registered (www.clinicaltrials.gov; NCT01128816), 
and its design, inclusion and exclusion criteria, and methods have been previously described [4].   
The analysis included all patients from 38 sites randomised into the ASVpf treatment arm of the 
ADVENT-HF study before March 31st, 2016, and for whom ASVpf adherence data were available at 
one and 12 months post-randomisation.  
ASVpf compliance, defined as the average hours of use per day, was calculated for all patients 
and separately for the obstructive (OSA) and central sleep apnea (CSA) groups. At one and 12 months, 
the percentage of patients compliant with ASVpf treatment, defined as use of more than 50% of the 
baseline total sleep time per day [4], and the percentage with good compliance, defined as use of 4 or 
more hours per day were assessed. For patients who withdrew from the study or who discontinued the 
device, hours of use were evaluated over the time during which the device was used and were imputed 
to be 0 hours per night after discontinuation.  
To define predictors of daily one-month ASVpf use, univariable logistic regression was 
performed with the following as independent variables: age, body mass index, sex, presence of coronary 
artery disease, atrial fibrillation or flutter, country of site, baseline values of AHI, Epworth Sleepiness 
Scale (ESS) score, sleep efficiency,  arousal index,  New York Heart Association class, N-terminal pro 
B-type natriuretic peptide, left ventricular ejection fraction,  Minnesota Living With Heart Failure 
Questionnaire scores, as well as type of mask used and leak at one month post-randomisation.  A similar 
analysis was performed for daily 12-month ASVpf with the addition of the independent variables, daily 
hours of ASVpf use at one month, as well as AHI, ESS, type of mask and leak at 12 months post-
randomisation. To define predictors of daily 12-month ASVpf use, a stepwise multiple regression 
analysis were performed.  
Of 177 subjects randomised to ASVpf, compliance data were available in 136 (91 with OSA and 
45 with CSA). Of the remainder, 27 did not attend the scheduled clinic visit and 14 either refused to 
participate or withdrew consent after randomization. Characteristics of those with OSA and CSA were 
similar, except for a higher AHI among CSA patients (37.4 [29.7] vs 50.8 [24.2], p=0.050).  
ASVpf was effective in controlling both OSA and CSA. In those with predominantly OSA, 
while on ASVpf, the AHI decreased from 42.7 ± 19.8 at baseline to 3.9 ± 2.7 one month later  to 3.3 ± 
2.8 12 twelve months later (p<0.01 for both). In those with predominantly CSA, while on ASVpf, the 
AHI decreased from 50.4 ± 16.7 at baseline to 5.3 ± 3.7 one month later and to 3.9 ± 2.5 twelve months 
later (p<0.01 for both). This compares to a residual AHI of 6.6 (mainly obstructive) 12 months post-
randomisation on ASVmv in the SERVE-HF trial.  
At one month a nasal mask was used by 93 (68%) of patients: 60 OSA (66%) and 33 CSA 
(73%). At 12 months the use of a nasal mask did not change: 86 (63%) of patients: 57 OSA (63%) and 
29 CSA (64%). The remainder used a full-face mask. 
By one month, of the 91 patients with OSA, only 3 (3%), had discontinued ASVpf, while among 
the 45 with CSA only one patient (2%) had discontinued it. At 12 months, they increased to 18 (20%) 
and 5 (11%), respectively, or 23 (17%) for all patients. The percentage of patients compliant [4] at 1 
month was 86% among OSA and 87% among CSA patients, at 12 months it was 67% and 80%, 
respectively. The median daily use for all 136 subjects at one month was 4.7 [3.2] h and declined to 4.4 
[4.3] h at 12 months (p < 0.01). As shown in Figure 1, daily ASVpf use declined from 4.6 to 4.1 hours 
per day in the OSA group, but remained stable at 5.2 h per day in the CSA group.   
 Among patients with OSA, 56 (62%) and 48 (53%) used ASVpf at least four hours per day at 
one and 12 months, respectively, while among patients with CSA, they were 30 (67%) and 27 (60%) at 
one and 12 months. No variable was a significant predictor of good compliance at one month. Hours of 
ASVpf use at one month was the only independent predictor of good ASVpf compliance at 12 months in 
the multivariate analysis of all patients (OR 2.02, CI 1.58-2.60, p<0.01) and in the subgroups separately 
(for OSA, OR 1.94: CI 1.27-2.78, p<0.01, for CSA, OR 2.12: CI 1.50-2.98, p<0.01).  
Both short and long-term ASVpf compliance were good in these patients with HFrEF and SDB 
enrolled in the ADVENT-HF trial.  
The “ASV  for CSA in Systolic HF” (SERVE-HF) trial showed that minute ventilation targeted 
ASV (ASVmv) had no effect on the primary endpoint possibly due, in part, to low ASVmv compliance  
of 3.4 hours per day at 12 months and 3.7 hours per day over the entire 5 year trial period [5, 6]. Only 
48% of patients used ASVmv at least 4 h per day over the trial period [2]. By contrast, ASVpf use in 
patients with CSA in the present study was higher in terms of hours of daily use and proportion using it 
at least 4 h per day after 12 months, although the proportion of patients who discontinued ASVpf 
increased from 2% at one to 11% at 12 months. Factors that might have contributed to better ASVpf 
compliance in the ADVENT-HF study include the technical characteristics of the ASVpf versus the 
ASVmv device used in SERVE-HF. ASVmv used relatively high default pressures with a minimum 
end-expiratory pressure (EPAP) of 5 cmH2O and minimum inspiratory pressure support of 3 cmH2O, 
whereas ASVpf in the present study used lower default pressures with a minimum EPAP of 4 cmH2O 
and a minimum pressure support of 0 cmH2O. These lower pressures might be better tolerated. In 
addition, unlike ASVmv that did not titrate EPAP to control obstructive events, ASVpf automatically 
titrates EPAP to control such events. This probably accounts for the lower residual AHI in patients on 
ASVpf, whether OSA or CSA, in the ADVENT-HF than in the SERVE-HF trial where residual events 
were mainly obstructive. Centralized versus local interpretation of ASVpf titrations and prescription of 
ASVpf settings in ADVENT-HF versus SERVE-HF as well as more frequent interaction with patients 
due to semi-annual versus annual follow-up visits in ADVENT-HF versus SERVE-HF may also have 
contributed to better ASVpf compliance. ASVpf compliance was also better in ADVENT-HF than 
ASVmv compliance in another recent RCT, in which daily use at 6 months was only 2.7 [7]. 
 Daily ASVpf use among patients with OSA in ADVENT-HF was also  higher than continuous 
positive airway pressure use in the “Sleep Apnea Cardiovascular Endpoints [SAVE]” trial (3.5 hours per 
day 12 months post-randomisation) [1]. However, in contrast to patients with CSA, daily hours of 
ASVpf use among those with OSA declined at 12 months, in association with an increase in patients 
discontinuing ASVpf. The reason for the reduction in use over time was not clear. Once the trial is 
complete, it will be possible to assess outcomes data to determine if any of them are related to ASVpf 
compliance.  
Recent RCTs testing CPAP therapy in non-sleepy OSA patients have demonstrated an absence 
of any effect on cardiovascular endpoints [1, 8, 9]. However, use of CPAP for >4 h per day was 
associated with a reduction in the incidence of the primary endpoint [8, 9]. Thus, there is a general 
tendency for PAP use of ≥ 4 hr per day to be associated with better outcomes. ASVpf has been shown to 
be more effective in suppressing OSA and CSA in patients with HFrEF than CPAP [5, 10, 11].  
The only factor that independently predicted daily hours of good ASVpf compliance  12 months 
post-randomisation was hours of ASVpf use at one month. These finding are compatible with previous 
evidence, indicating that patients’ initial experience with the treatment may influence their  long-term 
compliance [12, 13].  
Whether better adherence of ASVpf therapy in the present study than in previous studies of 
patients with cardiovascular diseases and SDB [1, 2, 7, 8] will be associated with better clinical 
outcomes will not be known until completion of the trial.   
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